TY  - JOUR

T1  - Cost-effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia A without inhibitors in the United States

JO  - PharmacoEconomics - Open

PY  - 2021/07/15

AU  - Bullement A

AU  - Knowles ES

AU  - DasMahapatra P

AU  - Ali T

AU  - Preblick R

ED  - 

DO  - DOI: 10.1007/s41669-021-00283-6

PB  - Springer Nature

Y2  - 2024/12/22

ER  -